Techalt, Inc.'s Stan's Rodeo Ointment (SRO) has Successful Introduction at the 2008...

Techalt, Inc.'s Stan's Rodeo Ointment (SRO) has Successful Introduction at the 2008 Beijing Olympics

SEATTLE--(Business Wire)--
Techalt, Inc. (Pink Sheets:TCLT) ("Techalt" or "Company")
announced that Stan's Rodeo Ointment ("SRO") was dispensed for use by
athletes at the 2008 Beijing Olympic Games. SportPharm, SRO's
compounder, and a U.S. Food and Drug Administration ("FDA") licensed
distributor, and subsidiary of HNP Pharmaceuticals, operated as a
member of the U.S. Olympic Medical Team and featured SRO for the
Olympic athletes and staff use at the Games.

Mike Pavlovich, Chief Pharmacist at SportPharm, conveyed his
excitement about the use of SRO at the Olympics and the positive
feedback he received. Pavlovich stated, "SRO was well received. I
spent a morning educating a number of Medical Doctors and ATC's
(Athletic Trainers Certified) about our various compounds. SRO and
Stan's Skin Toughner (SST) was used by the U.S. Olympic weightlifting,
baseball and track teams. In fact, one weightlifting coach commented
that he has a gym with '500' clients, and SRO would be a natural
complement."

Techalt is excited about SRO's contribution to the 2008 Beijing
Olympics. Techalt believes SRO will not only continue to penetrate the
professional athlete market, but expects to soon establish a base in
colleges, universities and high school campuses nationwide. In
connection with a marketing campaign specifically targeted to
collegiate and scholastic athletics.

Techalt has secured financing for expanding SRO's distribution
channels, securing contracts and obtaining over the counter approval
from the FDA.

About Techalt:

Techalt is a public holding company structured and designed to
pursue business in start-ups and developing, early to mid-stage
alternative technology, communications, environmental and health and
wellness companies.

About Stan's Rodeo Ointment ("SRO"):

SRO, currently available by prescription only, is a sports cream
product designed to accelerate the healing time for abrasions,
lacerations and blisters of the skin, while diminishing the pain that
often results from such injuries. Patent protection has been filed
covering the formulations and processing of SRO with the US Patent and
Trademark Office with a patent expected in 2008. For more information
about SRO and related products, access the link below:

http://www.sportpharm.com/stans/index.php

About HNP Pharmaceuticals ("HNP"):

HNP Pharmaceuticals is a nationally recognized pharmaceutical
compounding laboratory, specializing in unique and patent-pending
compounded formulations for orthopedic injuries. For more information
about HNP, access the link below:

http://www.hnppharmaceuticals.com/

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended ("the
Exchange Act"), as such, may involve risks and uncertainties.
Forward-looking statements are based upon certain assumptions and
describe future plans, strategies and expectations, are generally
identifiable by the use of words as "believe," "expect," "intend,"
"anticipate," "project," or other similar expressions. Forward-looking
statements relate to, among other things, future performance, and
perceived opportunities in the market and statements regarding the
Company's mission and vision. The Company's actual results,
performance and achievements may differ materially from the results,
performance, and achievements expressed or implied in such
forward-looking statements. Additional factors that could materially
affect these forward-looking statements and/or predictions include,
among other things: (1) its ability to manage and complete
acquisitions and to expand of operations; (2) obtaining necessary
financing to expands operations and manage existing debt; (3)
compliance with federal, state and local government and international
regulations; and (4) other factors over which we have little or no
control.

For Techalt, Inc.
Joseph J. Malone, 786-375-0556
Information@EquityDigest.com
www.EquityDigest.com

Copyright Business Wire 2008